BNOXBIONOMICS LIMITED/FI

Nasdaq bionomics.com.au


$ 0.66 $ -0.02 (-2.61 %)    

Wednesday, 18-Sep-2024 15:59:24 EDT
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ 0.641801
$ 0.63 x 596
-- x --
-- - --
$ 0.50 - $ 6.41
49,925
na
954.19M
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bionomics-receives-notice-of-allowance-for-us-patent-on-substituted-n-heteroaryl-compounds-for-cognitive-function-and-cns-disorders

https://patentcenter.uspto.gov/applications/17441637/ifw/docs

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-to-host-corporate-update-and-discuss-end-of-phase-2-meeting-outcomes-on-the-development-of-bnc210-in-ptsd-on-july-31-2024-at-800-am-et

Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class...

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-files-for-resale-of-up-to-364b-ordinary-shares-by-the-selling-shareholder

- SEC Filing 

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-reveals-detailed-data-from-ptsd-trial-stock-soars

Bionomics' Phase 2b ATTUNE trial on BNC210 for PTSD. Discover statistically significant improvements in symptom severity, c...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION